{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114437","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.675123+00:00","generated_at":"2026-06-22T07:58:27.132115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport Q3 revenue up 7% to $60.5M, cuts FY 2022 guidance to $232-$238M on macro headwinds","bullets":["Q3 revenue $60.5M (+7% YoY); net loss $7.3M ($0.15/share); adj. EBITDA $4.7M vs $6.0M YoY.","Full-year 2022 revenue guidance cut to $232-$238M, citing FX, COVID China, supply chain, Ukraine war headwinds.","Supported 643 global clinical trials (+61 YoY); entered apheresis partnership with Takeda's BioLife.","Cash $530M; repurchased 1.34M shares for $33.3M at avg $24.84; $100M program authorized through 2025.","Gross margin 43.7% (+222 bps YoY); operating costs rose 22% to $34.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114437","json":"https://secwatch.observer/filing/0001104659-22-114437.json","markdown":"https://secwatch.observer/filing/0001104659-22-114437.md","text":"https://secwatch.observer/filing/0001104659-22-114437.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922114437/0001104659-22-114437-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922114437/tm2229676d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:58:27.132115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26bb3dbd2a69cef3cacf8c859b5994a89e7ee0cc","claim":"Cryoport, Inc. reported the third quarter ended September 30, 2022 results: revenue $60.5 million. Guidance lowered.","evidence_excerpt":"Cryoport Reports Results for the Third Quarter 2022 § Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems’ revenue up 25% year-over-year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465922114437/0001104659-22-114437-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$60.5 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}